Abstract
1008
Objectives: Hematologic cancers are the fifth most commonly occurring cancers and the second leading cause of cancer death. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has proved to be useful in a variety of hematological malignancies, as there is increased glycolysis in the majority of these tumors, making visualization using FDG-PET/CT possible. In this educational exhibit we will provide an overview of the applications of PET imaging in hematological malignancies. Also, we will introduce novel methods of quantification of FDG uptake in these malignancies. 1. FDG-PET in Lymphoma: i: Diagnostics of lymphoma (staging of disease and planning for biopsy procedures) ii: Planning of radiotherapy for lymphomas iii: Assessment of response to treatment iv: Approach to transformation into highly malignant lymphoma 2. FDG-PET in Leukemia: i: Approach to Richter syndrome (RS) in chronic lymphoid leukemia (CLL) ii: Identification of extramedullary acute leukemia 3. FDG-PET in multiple myeloma (MM): i: Combined PET and low dose CT improves testing for osteolysis with less exposure to radiation ii: Detection of intramedullary and extramedullary lesions in MM iii: Estimation of tumor burden and prognosis (e.g. IMPETUS) iv: Evaluation of response to treatment (e.g. MRD measurement) 4. Novel quantification methods: i: Global lesion-based analysis using partial volume corrected total lesional glycolysis (pvcTLG) ii: Global segmentation of skeleton in FDG- and NaF-PET iii. Dual time point FDG-PET for correlation with lesion-based response to treatment 5. Potential of other radiotracers such as fluoromisonidazole (FMISO) and 3'-deoxy-3'-[18F] fluorothymidine (18F-FLT)